Does smoking cause vitiligo or make it spread?
I went looking for an answer in the main vitiligo guidance, and there is not one. NIAMS describes vitiligo as an autoimmune disease that attacks the cells making pigment. It says family history and genes may play a role. It names a short list of events that can sometimes trigger vitiligo or make it worse. Evidence Evidence Evidence
- Sunburn is on that list.
- Emotional distress is on it.
- Chemical exposure is on it.
- Tobacco and smoking are not.
Why this matters
- Sources cited, not yet graded
The British Association of Dermatologists guideline I read maps out assessment and treatment for vitiligo. The International Vitiligo Task Force recommendations cover assessment, disease activity and shared decisions. I checked both for smoking, and neither names it as a cause or a trigger.
Considerations
- Depends on you
A topic left out of a guideline is not a verdict on it. Silence is not proof of safety, and it is not proof of harm. So what I would do is name what you smoke at a review, and let the person treating you weigh it.
Questions for your dermatologist
I smoke about ___ a day. Does that change what you plan for my patches?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would quitting smoking alter the treatment you have picked for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does drinking alcohol make vitiligo worse?
The same gap sits here. Alcohol is not among the triggering events NIAMS names. I looked for a drinking limit in the British guideline, and it sets none. Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Whether alcohol, smoking or stress makes vitiligo worse is a question readers ask a lot, and the guidance answers less of it than you would hope. What the guideline does track is the weight of living with the condition. It tells clinicians to discuss that psychosocial impact. NIAMS names emotional distress among the events that can sometimes trigger vitiligo or make it worse. Drinking and distress often travel together, in both directions.
Considerations
- Depends on you
None of that makes alcohol a cause. A drink you remember and a patch you noticed later are not a chain of events. Your own pattern is still worth describing out loud, because it shapes sleep, mood and the rest of your care.
Questions for your dermatologist
I drink about ___ a week. Is that a problem alongside the treatment I am on?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Would cutting back change what you expect my skin to do?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Does alcohol matter if I take a pill for my vitiligo?
That question belongs to your prescriber, because pills carry their own boundaries. The European Medicines Agency overview for Rinvoq (upadacitinib), which I read, sets out EU safety restrictions. Evidence Evidence
- Severe liver problems are among them.
- So are tuberculosis and another serious infection.
- So is pregnancy.
- Extra caution applies for older adults, and for people with heart or cancer risk, where no suitable alternative exists.
Why this matters
- Sources cited, not yet graded
Litfulo (ritlecitinib) is a pill of the same drug family. I read its US label, which carries boxed warnings, a contraindication and other safety boundaries. Vitiligo is not among its current US indications.
Considerations
- Depends on you
I looked in both documents for a rule about drinking, and found none. So the answer for you comes from the person prescribing, alongside whatever blood tests they want to run. Ask before you assume a glass of wine is fine or that it is forbidden.
Questions for your dermatologist
I am starting ___. What do you want me to know about drinking while I take it?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which blood tests will you run for me, and what would make you change course?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Where do these habits actually touch my skin and my mood?
At the edges, and the edges still count. The American Academy of Dermatology says skin that has lost its color can burn readily, and that a bad sunburn can worsen vitiligo. NIAMS lists sunburn among triggering events too. A long night out in the sun is a real exposure, whatever you were drinking. Evidence Evidence Evidence Evidence
Why this matters
- Sources cited, not yet graded
Sleep is the other edge. I read the Centers for Disease Control and Prevention sleep page, and it names avoiding alcohol close to bedtime among general sleep habits. A steady sleep and wake schedule is on the same list. The British guideline asks clinicians to raise the psychosocial side of vitiligo, which is where poor sleep and low mood usually surface.
Considerations
- Depends on you
Skin ageing is a fair worry and a common one. I checked these vitiligo documents for a measure of how smoking ages skin, and there is none. There is none for skin without pigment either. So it stays a general health point rather than a vitiligo one.
Questions for your dermatologist
I drink most evenings and sleep badly. Should I raise that with you or with my GP?
Saving keeps this on your device and needs JavaScript, which is off in this browser.My mood has dropped since my patches spread. Who do you refer people to?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What can I expect if I stop smoking or cut back on drinking?
Real gains for your health, and nothing you should count on for your color. The British guideline names what is used to bring pigment back, and I could not find either habit in that map. Evidence Evidence
- R10 to R14 name potent or very potent topical steroids as the first choice.
- A topical calcineurin-inhibitor cream is an option for the face.
- R20 names narrowband UVB as the first light option.
- Skin often does better on the face and trunk than on hands and feet.
Why this matters
- Sources cited, not yet graded
Any dermatologist will back stopping smoking and moderating alcohol, for your heart, your lungs and your general health. The task force recommendations also separate active vitiligo from stable vitiligo, because the state of the disease changes the plan.
Considerations
- Depends on you
What nobody can promise is repigmentation from a habit change alone. Treat a change you make as something to record, not as a treatment. Write down the week you stopped or cut back, and keep photos in the same light. Then your next review has something real to read.
Questions for your dermatologist
I stopped smoking ___ weeks ago. What would you look for at my next review?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Someone sold me a quit-and-repigment program. How would you check a claim like that?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- American Academy of DermatologyPatient education · Patient education, tier 5Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports patient-facing context that skin which has lost its color can burn readily and that shade, clothing and labeled sunscreen use are broad protection options. It also supports that for some people a skin injury triggers new spots or patches, and it names cuts, scrapes and burns. The wound a tattoo makes can lead to the Koebner phenomenon, with new spots appearing about 10 to 14 days later. It supports that a tattoo added for pigment may not blend with natural skin color, that its color can eventually bleed, and that the vitiligo underneath can spread over time. It supports the page telling readers to avoid tanning, indoors and outdoors, because tanning increases the contrast between natural skin color and the light spots and patches. That is what it says makes vitiligo more noticeable. It supports that tanning beds, sun lamps and other indoor tanning devices are not safe alternatives to the sun. Like the sun, they can burn skin that has lost pigment and worsen vitiligo. It supports that a bad sunburn can worsen vitiligo, and that on a lighter skin tone untanned skin often makes the spots and patches less noticeable. It supports that self-tanners and skin dyes tend to last 3 to 5 days, against one day for makeup. It names dihydroxyacetone as the ingredient to look for, and says natural-looking results take practice. It supports that vitiligo increases the risk of some other diseases such as thyroid disease, and that a dermatologist can monitor for them.
What it does not support
The page acknowledges support from Incyte Dermatology, so it does not independently establish treatment efficacy. It does not establish a personalized sun plan, a product ranking or a treatment-day instruction. It gives no frequency for injury-related patches and no way to tell in advance who they happen to. It gives no measure of how much tanning changes contrast, no threshold for a bad sunburn, and no way to tell whether one person’s vitiligo will worsen. It compares no tanning device with prescribed narrowband UVB and establishes nothing about medical phototherapy. It names no product or brand for camouflage, self-tanner or skin dye.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- National Institute of Arthritis and Musculoskeletal and Skin DiseasesPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports that vitiligo is an autoimmune disease in which the immune system attacks melanocytes. Researchers believe family history and genes may play a role. An event such as sunburn, emotional distress, or chemical exposure can sometimes trigger vitiligo or make it worse. These are contributing factors, not a single determined cause repeated in every case.
What it does not support
It does not state that there is no single known cause. It does not rule out a specific trigger for one individual. It does not let a reader diagnose their own cause from a remembered event or timeline.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Centers for Disease Control and PreventionGuideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: US federal public-health agency; general population guidance, no product or manufacturer tie.
What this source supports
Supports general sleep-hygiene habits for the general population. A consistent sleep and wake schedule, in a cool and quiet bedroom. Turning off electronic devices at least 30 minutes before bed. Avoiding large meals, alcohol and caffeine close to bedtime. Regular exercise.
What it does not support
Is not specific to vitiligo, does not claim these habits treat any skin condition, and does not address a diagnosed sleep disorder, which needs a clinician.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- European Medicines AgencyRegulatory · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the EMA safety overview, including EU restrictions concerning tuberculosis or another serious infection, severe liver problems, pregnancy, and additional caution when no suitable alternative exists for older adults or people with cardiovascular or cancer risk. It does not calculate personal risk, establish reimbursement, or supply a vitiligo regimen.
What it does not support
The product-information document linked from this page was dated before the July 24, 2026 vitiligo authorization decision and must not be treated as the source of the new vitiligo indication.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
Litfulo (ritlecitinib): current US prescribing information and Medication Guide (opens in a new tab)
DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Relevant relationship disclosed- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The National Library of Medicine hosts DailyMed. The product company submits the label to FDA, so it is authoritative for current US labeling but not independent efficacy evidence.
What this source supports
Supports Litfulo identity, its current US severe-alopecia indication, boxed warnings, contraindication and other label safety boundaries. Vitiligo is not among the current US indications. Also supports the recommended dosage for the approved indication: 50 mg orally once daily, with or without food, with no loading dose or titration.
What it does not support
The alopecia label does not establish a vitiligo indication, vitiligo-specific event rates, individual suitability, coverage, a vitiligo regimen or approval in another jurisdiction.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.